TME Pharma N.V. (ALTME.PA)
- Previous Close
0.0634 - Open
0.0650 - Bid --
- Ask --
- Day's Range
0.0640 - 0.0698 - 52 Week Range
0.0592 - 0.2600 - Volume
1,810,122 - Avg. Volume
263,573 - Market Cap (intraday)
6.387M - Beta (5Y Monthly) 1.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.61
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
www.tmepharma.comRecent News: ALTME.PA
View More
Performance Overview: ALTME.PA
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALTME.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALTME.PA
View MoreValuation Measures
Market Cap
5.97M
Enterprise Value
2.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-111.45%
Return on Equity (ttm)
-866.97%
Revenue (ttm)
19k
Net Income Avi to Common (ttm)
-5.72M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.73M